APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global VEGF Inhibitor Drugs Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchVEGF Inhibitor Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitor Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitor Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitor Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global VEGF Inhibitor Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for VEGF Inhibitor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for VEGF Inhibitor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for VEGF Inhibitor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for VEGF Inhibitor Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of VEGF Inhibitor Drugs include Sanofi, Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer, GlaxoSmithKline plc, Bayer AG, Genentech, Inc. (Roche) and Bristol-Myers-Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for VEGF Inhibitor Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of VEGF Inhibitor Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for VEGF Inhibitor Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the VEGF Inhibitor Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global VEGF Inhibitor Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for VEGF Inhibitor Drugs revenue, projected growth trends, production technology, application and end-user industry.

VEGF Inhibitor Drugs Segment by Company

Sanofi

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer

GlaxoSmithKline plc

Bayer AG

Genentech, Inc. (Roche)

Bristol-Myers-Squibb Company

AstraZeneca plc

VEGF Inhibitor Drugs Segment by Type

Tyrosine Kinase Inhibitors

Monoclonal Antibodies

Others

VEGF Inhibitor Drugs Segment by Application

Oncology

Ophthalmology

Others

VEGF Inhibitor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of VEGF Inhibitor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of VEGF Inhibitor Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, VEGF Inhibitor Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tyrosine Kinase Inhibitors Major Player Table 3. Monoclonal Antibodies Major Player Table 4. Others Major Player Table 5. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Oncology Major Player Table 7. Ophthalmology Major Player Table 8. Others Major Player Table 9. VEGF Inhibitor Drugs Industry Trends Table 10. VEGF Inhibitor Drugs Industry Drivers Table 11. VEGF Inhibitor Drugs Industry Opportunities and Challenges Table 12. VEGF Inhibitor Drugs Industry Restraints Table 13. Global VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global VEGF Inhibitor Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global VEGF Inhibitor Drugs Market Share by Region (2021-2026) Table 16. Global VEGF Inhibitor Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global VEGF Inhibitor Drugs Market Share by Region (2027-2032) Table 18. Global VEGF Inhibitor Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global VEGF Inhibitor Drugs Revenue Market Share by Players (2021-2026) Table 20. Global VEGF Inhibitor Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global VEGF Inhibitor Drugs Key Players Headquarters & Area Served Table 22. Global VEGF Inhibitor Drugs Players, Product Type & Application Table 23. Global VEGF Inhibitor Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global VEGF Inhibitor Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global VEGF Inhibitor Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2021-2026) Table 30. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2027-2032) Table 31. Global VEGF Inhibitor Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021-2026) Table 35. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi VEGF Inhibitor Drugs Product Portfolio Table 40. Sanofi Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG VEGF Inhibitor Drugs Product Portfolio Table 45. Novartis AG Recent Development Table 46. Merck & Co., Inc. Company Information Table 47. Merck & Co., Inc. Business Overview Table 48. Merck & Co., Inc. VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio Table 50. Merck & Co., Inc. Recent Development Table 51. Eli Lilly & Company Company Information Table 52. Eli Lilly & Company Business Overview Table 53. Eli Lilly & Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio Table 55. Eli Lilly & Company Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer VEGF Inhibitor Drugs Product Portfolio Table 60. Pfizer Recent Development Table 61. GlaxoSmithKline plc Company Information Table 62. GlaxoSmithKline plc Business Overview Table 63. GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio Table 65. GlaxoSmithKline plc Recent Development Table 66. Bayer AG Company Information Table 67. Bayer AG Business Overview Table 68. Bayer AG VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Bayer AG VEGF Inhibitor Drugs Product Portfolio Table 70. Bayer AG Recent Development Table 71. Genentech, Inc. (Roche) Company Information Table 72. Genentech, Inc. (Roche) Business Overview Table 73. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio Table 75. Genentech, Inc. (Roche) Recent Development Table 76. Bristol-Myers-Squibb Company Company Information Table 77. Bristol-Myers-Squibb Company Business Overview Table 78. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio Table 80. Bristol-Myers-Squibb Company Recent Development Table 81. AstraZeneca plc Company Information Table 82. AstraZeneca plc Business Overview Table 83. AstraZeneca plc VEGF Inhibitor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio Table 85. AstraZeneca plc Recent Development Table 86. North America VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 87. North America VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 88. North America VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 89. North America VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 90. North America VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America VEGF Inhibitor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 92. North America VEGF Inhibitor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 93. Europe VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 94. Europe VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 95. Europe VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 96. Europe VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 97. Europe VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe VEGF Inhibitor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 99. Europe VEGF Inhibitor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 100. China VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 101. China VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 102. China VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 103. China VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 105. Asia VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 106. Asia VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 107. Asia VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia VEGF Inhibitor Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia VEGF Inhibitor Drugs Revenue by Region (US$ Million) & (2021-2026) Table 110. Asia VEGF Inhibitor Drugs Revenue by Region (US$ Million) & (2027-2032) Table 111. SAMEA VEGF Inhibitor Drugs Revenue by Type (2021-2026) & (US$ Million) Table 112. SAMEA VEGF Inhibitor Drugs Revenue by Type (2027-2032) & (US$ Million) Table 113. SAMEA VEGF Inhibitor Drugs Revenue by Application (2021-2026) & (US$ Million) Table 114. SAMEA VEGF Inhibitor Drugs Revenue by Application (2027-2032) & (US$ Million) Table 115. SAMEA VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. SAMEA VEGF Inhibitor Drugs Revenue by Country (2021-2026) & (US$ Million) Table 117. SAMEA VEGF Inhibitor Drugs Revenue by Country (US$ Million) & (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. VEGF Inhibitor Drugs Image Figure 2. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Inhibitor Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tyrosine Kinase Inhibitors Image Figure 5. Monoclonal Antibodies Image Figure 6. Others Image Figure 7. Global VEGF Inhibitor Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global VEGF Inhibitor Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Oncology Image Figure 10. Ophthalmology Image Figure 11. Others Image Figure 12. Global VEGF Inhibitor Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global VEGF Inhibitor Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global VEGF Inhibitor Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global VEGF Inhibitor Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global VEGF Inhibitor Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global VEGF Inhibitor Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global VEGF Inhibitor Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America VEGF Inhibitor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America VEGF Inhibitor Drugs Revenue Share by Type (2021-2032) Figure 25. North America VEGF Inhibitor Drugs Revenue Share by Application (2021-2032) Figure 26. North America VEGF Inhibitor Drugs Revenue Share by Country (2021-2032) Figure 27. United States VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe VEGF Inhibitor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe VEGF Inhibitor Drugs Revenue Share by Type (2021-2032) Figure 32. Europe VEGF Inhibitor Drugs Revenue Share by Application (2021-2032) Figure 33. Europe VEGF Inhibitor Drugs Revenue Share by Country (2021-2032) Figure 34. Germany VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China VEGF Inhibitor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China VEGF Inhibitor Drugs Revenue Share by Type (2021-2032) Figure 44. China VEGF Inhibitor Drugs Revenue Share by Application (2021-2032) Figure 45. Asia VEGF Inhibitor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia VEGF Inhibitor Drugs Revenue Share by Type (2021-2032) Figure 47. Asia VEGF Inhibitor Drugs Revenue Share by Application (2021-2032) Figure 48. Asia VEGF Inhibitor Drugs Revenue Share by Region (2021-2032) Figure 49. Japan VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA VEGF Inhibitor Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA VEGF Inhibitor Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA VEGF Inhibitor Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA VEGF Inhibitor Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt VEGF Inhibitor Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Monoclonal Antibodies
  • Others
Applications
  • Oncology
  • Ophthalmology
  • Others
Companies covered
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer
  • GlaxoSmithKline plc
  • Bayer AG
  • Genentech, Inc. (Roche)
  • Bristol-Myers-Squibb Company
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 VEGF Inhibitor Drugs Market by Type
  3. 1.2.1 Global VEGF Inhibitor Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tyrosine Kinase Inhibitors
  5. 1.2.3 Monoclonal Antibodies
  6. 1.2.4 Others
  7. 1.3 VEGF Inhibitor Drugs Market by Application
  8. 1.3.1 Global VEGF Inhibitor Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology
  10. 1.3.3 Ophthalmology
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 VEGF Inhibitor Drugs Market Dynamics
  1. 2.1 VEGF Inhibitor Drugs Industry Trends
  2. 2.2 VEGF Inhibitor Drugs Industry Drivers
  3. 2.3 VEGF Inhibitor Drugs Industry Opportunities and Challenges
  4. 2.4 VEGF Inhibitor Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global VEGF Inhibitor Drugs Market Perspective (2021-2032)
  2. 3.2 Global VEGF Inhibitor Drugs Growth Trends by Region
  3. 3.2.1 Global VEGF Inhibitor Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global VEGF Inhibitor Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global VEGF Inhibitor Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global VEGF Inhibitor Drugs Revenue by Players
  2. 4.1.1 Global VEGF Inhibitor Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global VEGF Inhibitor Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global VEGF Inhibitor Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global VEGF Inhibitor Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global VEGF Inhibitor Drugs Key Players Headquarters & Area Served
  7. 4.4 Global VEGF Inhibitor Drugs Players, Product Type & Application
  8. 4.5 Global VEGF Inhibitor Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global VEGF Inhibitor Drugs Market CR5 and HHI
  11. 4.6.3 2025 VEGF Inhibitor Drugs Tier 1, Tier 2, and Tier 3
5 VEGF Inhibitor Drugs Market Size by Type
  1. 5.1 Global VEGF Inhibitor Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 5.3 Global VEGF Inhibitor Drugs Revenue Market Share by Type (2021-2032)
6 VEGF Inhibitor Drugs Market Size by Application
  1. 6.1 Global VEGF Inhibitor Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  3. 6.3 Global VEGF Inhibitor Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi VEGF Inhibitor Drugs Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG VEGF Inhibitor Drugs Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Merck & Co., Inc.
  14. 7.3.1 Merck & Co., Inc. Company Information
  15. 7.3.2 Merck & Co., Inc. Business Overview
  16. 7.3.3 Merck & Co., Inc. VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio
  18. 7.3.5 Merck & Co., Inc. Recent Developments
  19. 7.4 Eli Lilly & Company
  20. 7.4.1 Eli Lilly & Company Company Information
  21. 7.4.2 Eli Lilly & Company Business Overview
  22. 7.4.3 Eli Lilly & Company VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio
  24. 7.4.5 Eli Lilly & Company Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer VEGF Inhibitor Drugs Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GlaxoSmithKline plc
  32. 7.6.1 GlaxoSmithKline plc Company Information
  33. 7.6.2 GlaxoSmithKline plc Business Overview
  34. 7.6.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio
  36. 7.6.5 GlaxoSmithKline plc Recent Developments
  37. 7.7 Bayer AG
  38. 7.7.1 Bayer AG Company Information
  39. 7.7.2 Bayer AG Business Overview
  40. 7.7.3 Bayer AG VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bayer AG VEGF Inhibitor Drugs Product Portfolio
  42. 7.7.5 Bayer AG Recent Developments
  43. 7.8 Genentech, Inc. (Roche)
  44. 7.8.1 Genentech, Inc. (Roche) Company Information
  45. 7.8.2 Genentech, Inc. (Roche) Business Overview
  46. 7.8.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio
  48. 7.8.5 Genentech, Inc. (Roche) Recent Developments
  49. 7.9 Bristol-Myers-Squibb Company
  50. 7.9.1 Bristol-Myers-Squibb Company Company Information
  51. 7.9.2 Bristol-Myers-Squibb Company Business Overview
  52. 7.9.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio
  54. 7.9.5 Bristol-Myers-Squibb Company Recent Developments
  55. 7.10 AstraZeneca plc
  56. 7.10.1 AstraZeneca plc Company Information
  57. 7.10.2 AstraZeneca plc Business Overview
  58. 7.10.3 AstraZeneca plc VEGF Inhibitor Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio
  60. 7.10.5 AstraZeneca plc Recent Developments
8 North America
  1. 8.1 North America VEGF Inhibitor Drugs Revenue (2021-2032)
  2. 8.2 North America VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America VEGF Inhibitor Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America VEGF Inhibitor Drugs Revenue by Type (2027-2032)
  5. 8.3 North America VEGF Inhibitor Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America VEGF Inhibitor Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America VEGF Inhibitor Drugs Revenue by Application (2027-2032)
  9. 8.5 North America VEGF Inhibitor Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America VEGF Inhibitor Drugs Revenue by Country
  11. 8.6.1 North America VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America VEGF Inhibitor Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America VEGF Inhibitor Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe VEGF Inhibitor Drugs Revenue (2021-2032)
  2. 9.2 Europe VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe VEGF Inhibitor Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe VEGF Inhibitor Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe VEGF Inhibitor Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe VEGF Inhibitor Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe VEGF Inhibitor Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe VEGF Inhibitor Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe VEGF Inhibitor Drugs Revenue by Country
  11. 9.6.1 Europe VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe VEGF Inhibitor Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe VEGF Inhibitor Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China VEGF Inhibitor Drugs Revenue (2021-2032)
  2. 10.2 China VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China VEGF Inhibitor Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China VEGF Inhibitor Drugs Revenue by Type (2027-2032)
  5. 10.3 China VEGF Inhibitor Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China VEGF Inhibitor Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China VEGF Inhibitor Drugs Revenue by Application (2027-2032)
  9. 10.5 China VEGF Inhibitor Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia VEGF Inhibitor Drugs Revenue (2021-2032)
  2. 11.2 Asia VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia VEGF Inhibitor Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia VEGF Inhibitor Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia VEGF Inhibitor Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia VEGF Inhibitor Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia VEGF Inhibitor Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia VEGF Inhibitor Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia VEGF Inhibitor Drugs Revenue by Country
  11. 11.6.1 Asia VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia VEGF Inhibitor Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia VEGF Inhibitor Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA VEGF Inhibitor Drugs Revenue (2021-2032)
  2. 12.2 SAMEA VEGF Inhibitor Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA VEGF Inhibitor Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA VEGF Inhibitor Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA VEGF Inhibitor Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA VEGF Inhibitor Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA VEGF Inhibitor Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA VEGF Inhibitor Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA VEGF Inhibitor Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA VEGF Inhibitor Drugs Revenue by Country
  11. 12.6.1 SAMEA VEGF Inhibitor Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA VEGF Inhibitor Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA VEGF Inhibitor Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst